Status:
TERMINATED
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
Lead Sponsor:
University of Florida
Collaborating Sponsors:
National Pediatric Cancer Foundation
National Cancer Institute (NCI)
Conditions:
Malignant Glioma
High Grade Glioma
Eligibility:
All Genders
3-21 years
Phase:
PHASE1
Brief Summary
It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special pr...
Detailed Description
It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special pr...
Eligibility Criteria
Inclusion
- Screening Eligibility:
- Patients with histologically confirmed WHO Grade III or IV malignant glioma
- Scheduled for definitive surgical resection of suspected HGG (biopsy only subjects are not eligible for this study)
- Post-Surgical Resection Eligibility
- Histologically confirmed WHO Grade III or IV malignant glioma
- Karnofsky Performance Status (KPS) of ≥ 60% (KPS for ≥ 16 years of age) or Lansky performance Score (LPS) of ≥ 60 (LPS for \< 16 years of age) assessed within 2 weeks prior to registration
- Bone Marrow: ANC (Absolute neutrophil count) ≥ 1000/µl (unsupported); Platelets ≥ 100,000/µl (unsupported for at least 3 days); Hemoglobin \> 8 g/dL (may be supported)
- Renal:Serum creatinine ≤ upper limit of institutional normal
- Hepatic: Bilirubin ≤ 1.5 times upper limit of institutional normal for age. SGPT (ALT) ≤ 3 times upper limit of institutional normal for age. SGOT (AST) ≤ 3 times upper limit of institutional normal for age.
- Signed informed consent according to institutional guidelines.
- Patient or patient guardian consent to PBSC harvest following registration.
- Subjects of childbearing or child-fathering potential must be willing to use medically acceptable forms of birth control while being treated on this study.
- Subjects with post-surgical neurological deficits should have deficits that are stable for a minimum of 1 week prior to leukapheresis.
- Exclusion Criteria:
- Pregnant or need to breast feed during the study period (Negative serum pregnancy test required).
- Known autoimmune or immunosuppressive disease or human immunodeficiency virus infection.
- Subjects with significant renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), pulmonary, hepatic or other organ dysfunction.
- Severe or unstable concurrent medical conditions.
- Prior allergic reaction to TMZ, GM-CSF, or Td
- Subjects who are unwilling or unable to receive treatment and undergo follow-up evaluations at the enrolled Sunshine Project Consortium treatment site.
Exclusion
Key Trial Info
Start Date :
May 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 20 2025
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03334305
Start Date
May 16 2018
End Date
March 20 2025
Last Update
October 2 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's of Alabama at UAB
Birmingham, Alabama, United States, 35233
2
Children's National Hospital
Washington D.C., District of Columbia, United States, 20010
3
UF Health Shands Children's Hospital
Gainesville, Florida, United States, 32608